Skip to main content

Heparin drug delivery system for prevention of posterior capsular opacification in rabbit eyes

Graefe's Archive for Clinical and Experimental Ophthalmology volume 241, pages 309–313 (2003)Cite this article

Abstract

Background

The aim of this study was to investigate the safety and efficacy of a heparin drug delivery system (HEP DDS) for prevention of posterior capsular opacification (PCO) in rabbits.

Methods

Fifty New Zealand albino rabbits (50 eyes) undergoing phacoemulsification were equally divided into five groups receiving normal saline eye drops (group A), a carrier DDS implanted into the posterior chamber (group B), 5% heparin eye drops (group C), a HEP DDS implanted subconjunctivally (group D) and a HEP DDS implanted into the posterior chamber (group E). All the 50 eyes were examined by slit-lamp microscopy. The heparin levels in blood and aqueous humor were measured, and the wet posterior capsules were weighed.

Results

All eyes in groups A and B had PCO at 5–7 days, much earlier than in groups C, D and E. Two eyes in group C, three eyes in group D and six eyes in group E showed no signs of PCO throughout the 12-week study. The mean weight of wet posterior capsules from groups A–E was 157.919 mg, 160.091 mg, 81.114 mg, 71.827 mg and 19.984 mg respectively. The mean aqueous humor heparin level in groups C, D and E was 10.279 μg/ml, 13.246 μg/ml and 25.964 μg/ml respectively. Cell proliferation of the posterior capsules in group E was not active. The conjunctiva, cornea, iris, ciliary body and retina remained intact, and no significant toxic reactions were observed. No intraocular hemorrhage occurred during the follow-up.

Conclusion

Implantation of a HEP DDS into the posterior chamber of experimental animals significantly maintained a higher heparin level in aqueous humor for a relatively long period of time. The findings indicate potential prevention of PCO with minimum toxic and side effects.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

43,34 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

Fig. 1.

References

  1. Apple DJ, Kincaid MC, Mamalis N, Olson RJ (1989) Intraocular lenses: evolution, designs, complications and pathology. Williams & Wilkins, Baltimore, MD

    Google Scholar 

  2. Del Vecchio PJ, Bizios R, Holleran LA, Judge TK, Pinto GL (1988) Inhibition of human scleral fibroblast proliferation with heparin. Invest Ophthalmol Vis Sci 29:1272–1276

    PubMed  Google Scholar 

  3. Gallenga PE, Mastropasqua L, Lobefalo L (1986) L'uso dell' eparina nel trattamento dei depositi pigmentari delle IOLs. Atti International Congress Aspetti Oftalmologici di Interesse Interdisciplinare. Parte I. Vibo Valentia 57–61

  4. Lu B (1998) New drug forms and techniques. People's Medical Publishing House, Beijing

  5. Murray TG, Stern WH, Chin DH, MacGowan-Smith EA (1990) Collagon shield heparin delivery for prevention of postoperative fibrin. Arch Ophthalmol 108:104–106

    CAS  PubMed  Google Scholar 

  6. Nishi O (1986) Incidence of posterior capsule opacification in eyes with and without posterior chamber intraocular lenses. J Cataract Refract Surg 12:519–522

    CAS  PubMed  Google Scholar 

  7. Odrich MG, Hall SJ, Worgul BV, Trokel SL, Rini FJ (1985) Posterior capsule opacification: experimental analyses. Ophthalmic Res 17:75–84

    CAS  PubMed  Google Scholar 

  8. Wang X, Li J, Ma F, Yu X, Li R, Yang G (1999) An experimental study on the prevention of posterior capsular opacification by using heparinized irrigating solution. Chin Ophthalmic Res 17:341–342

    CAS  Google Scholar 

  9. Xia X, Lu D, Wang L, Chen C, Wu N (1994) Experimental study on the inhibition of aftercataract occurrence by heparin. Recent Adv Ophthalmol 14(4):6–8

    Google Scholar 

  10. Yang P, Li S (1998) Uveitis. People's Medical Publishing House, Beijing

  11. Yasukawa T, Kimura H, Tabata Y, Miyamoto H, Honda Y, Ogura Y (2002) Sustained release of cis-hydroxyproline in the treatment of experimental proliferative vitreoretinopathy in rabbits. Graefes Arch Clin Exp Ophthalmol 240:672–678

    CAS  PubMed  Google Scholar 

Download references

Acknowledgements

This study was supported by Shandong Province Science and Technology Bureau, China (012130121), and in part by the National High Technology Research and Development Program of China (863 Program), the Ministry of Science and Technology, China (2002AA2Z3136). The authors would like to thank Ms Ping Lin for editing this manuscript.

Author information

Affiliations

  1. Shandong Eye Institute & Hospital, 5 Yanerdao Road, 266071, Qingdao , PR China

    Lixin Xie, Jie Sun & Zhan Yao

Authors
  1. Lixin Xie
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jie Sun
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Zhan Yao
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Lixin Xie.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Xie, L., Sun, J. & Yao, Z. Heparin drug delivery system for prevention of posterior capsular opacification in rabbit eyes. Graefe's Arch Clin Exp Ophthalmol 241, 309–313 (2003). https://doi.org/10.1007/s00417-003-0645-5

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00417-003-0645-5

Keywords

  • Flare
  • Aqueous Humor
  • Ciliary Body
  • Posterior Capsule
  • Lens Epithelial Cell